» Articles » PMID: 8199566

Graft Rejection and Second Bone Marrow Transplants for Acquired Aplastic Anaemia: a Report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group

Overview
Specialty General Surgery
Date 1994 Mar 1
PMID 8199566
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Six hundred and eighteen patients with acquired aplastic anaemia grafted from an HLA-identical sibling donor between 1976 and 1990 in eight European centres were reported to the Working Party for Severe Aplastic Anaemia (SAA) Registry and were evaluable for analysis of the incidence of graft failure/rejection and the outcome of second bone marrow transplants (BMT). The number of patients experiencing graft rejection declined significantly over the study period from 32% to 8% (p < 0.0001). This coincided with the introduction of cyclosporine to the conditioning regimen for BMT. The graft rejection rate in the post-hepatitis SAA group was significantly lower than in the group with idiopathic SAA (4% vs 20%) (p = 0.001). The use of irradiation in the conditioning regimen significantly reduced the number of patients experiencing graft rejection (7% vs 21%) (p = 0.004). Age, sex and severity of disease did not influence the rate of sustained engraftment. Of the 85 patients experiencing graft rejection, 41 received a second transplant: their survival is 33% vs 8% for patients not transplanted a second time (p = 0.003). The major factor predicting the outcome of second BMT for SAA was the interval from first BMT. Patients receiving a second BMT within 60 days from the first BMT had a significantly poorer outcome.

Citing Articles

Graft failure after allogeneic hematopoietic stem cell transplantation in pediatric patients with acute leukemia: autologous reconstitution or second transplant?.

Rostami T, Rostami M, Mirhosseini A, Mohammadi S, Nikbakht M, Alemi H Stem Cell Res Ther. 2024; 15(1):111.

PMID: 38644499 PMC: 11034046. DOI: 10.1186/s13287-024-03726-z.


Outcome of Second Allogeneic HSCT for Patients with Inborn Errors of Immunity: Retrospective Study of 20 Years' Experience.

Mehta P, Tsilifis C, Lum S, Slatter M, Hambleton S, Owens S J Clin Immunol. 2023; 43(8):1812-1826.

PMID: 37452206 DOI: 10.1007/s10875-023-01549-w.


Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities.

Olson T, Frost B, Duke J, Dribus M, Xie H, Prudowsky Z JCI Insight. 2022; 7(22).

PMID: 36219480 PMC: 9746824. DOI: 10.1172/jci.insight.163040.


Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders.

Albert M, Sirin M, Hoenig M, Hauck F, Schuetz C, Bhattacharyya R Bone Marrow Transplant. 2021; 56(9):2248-2258.

PMID: 33967276 PMC: 8106764. DOI: 10.1038/s41409-021-01323-9.


Graft failure.

McCann S Bone Marrow Transplant. 2020; 55(10):1888-1889.

PMID: 32161320 DOI: 10.1038/s41409-020-0860-2.